English 
Español
Published: September 20, 2019
Validation of a Cell Proliferation Assay to Assess the Potency of a Dialyzable Leukocyte Extract Intended for Batch Release.
Related Articles
-
UDIBI
Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc región....
-
UDIBI
Published: march 20, 2021 Consistency of a dialyzable leucocyte extract manufactured at GMPfacilities by Nuclear magnetic resonance spectroscopy More...
-
UDIBI
Published: april 2nd, 2020 Development and Evaluation of a Set of Spike and Receptor Binding Domain‐Based Enzyme‐Linked Immunosorbent Assays...
-
UDIBI
Published : March 2021 Poor survival in COVID-19 associated with Lymphopenia and Higher Neutrophile-Lymphocyte ratio More information
-
UDIBI
SARS-CoV-2 Omicron Antibodies Isolated from a SARS-CoV-2 Delta Semi-Immune Phage Display Library SHOW MORE
-
UDIBI
Efficacy, Pharmacokinetics, and Toxicity Profiles of Broad Anti-SARS-CoV-2 Neutralizing Antibody. SHOW MORE
-
UDIBI
Published: September, 2019 A differential sex-specific pattern of IgG2 and IgG4 subclasses of anti-drug antibodies (ADAs) induced by glatiramer...
-
UDIBI
Validation of a cell proliferation assay to assess the potency of a Dialyzable Leucocyte Extract intended for batch release....
0 Comments
